Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport
Parkinson’s disease (PD) is characterized by neurodegeneration of nigral-striatal neurons in parallel with the formation of intra-neuronal α-synuclein aggregates, and these processes are exacerbated by neuro-inflammation. All 3 components of PD pathology are potentially treatable with biologics. Neu...
Main Author: | William M. Pardridge |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2023.1276376/full |
Similar Items
-
Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor
by: William M. Pardridge
Published: (2021-12-01) -
Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor
by: William M. Pardridge, et al.
Published: (2021-06-01) -
The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier
by: William M. Pardridge
Published: (2020-05-01) -
Anti-Parkinsonian Therapy: Strategies for Crossing the Blood–Brain Barrier and Nano-Biological Effects of Nanomaterials
by: Guowang Cheng, et al.
Published: (2022-04-01) -
Advancements in the Blood–Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications
by: Suresh Thangudu, et al.
Published: (2020-12-01)